Senolytic Supplements Ranked by Evidence — What the Research Actually Shows

Longevity supplement sales have surged on the back of compelling preclinical data, but translating mouse lifespan results to human healthspan benefit has proven difficult. This product review systematically evaluates popular senolytic and longevity supplement stacks — including fisetin, quercetin, resveratrol, and spermidine, both as standalone products and in branded multi-ingredient formulas — and grades each on evidence quality, pricing, and practical purchasing considerations.

Across all categories reviewed, no product or stack has large randomized-trial evidence showing extended human lifespan or reliably slowed biological aging. Quercetin ranks highest among the four compounds for its modest but real effects on selected inflammatory, vascular, and related biomarkers, though this does not translate to a demonstrated longevity benefit. Spermidine is rated second due to its mechanistically credible autophagy pathway and encouraging preclinical data, with a handful of early human studies providing partial support.

Resveratrol, despite decades of sirtuin-activation research and a massive animal literature, consistently underdelivers in human trials, with effects on metabolic, inflammatory, and cardiovascular outcomes described as modest or null. Fisetin ranks last for human applicability: mouse senolytic findings are striking, but clinical dosing, bioavailability, and safety in people remain unresolved. The review explicitly warns against assuming rodent lifespan gains predict human outcomes.

Multi-ingredient commercial stacks such as Perpetua.Life AEON and Blueprint Longevity Mix offer convenience but complicate interpretation: evidence applies to individual ingredients at specific doses, not finished branded products. Liposomal delivery claims, as seen with LILICARE fisetin, should not be equated with proven clinical benefit without supporting human data.

For clinicians and health-conscious consumers, the practical guidance is consistent: prioritize products with transparent ingredient doses, independent contaminant and purity testing, and conservative marketing claims. Fisetin and quercetin may interact with medications affecting bleeding and drug metabolism, warranting caution in polypharmacy patients.